Targeted therapy for metastatic renal cell carcinoma.
Explore this paper's citation graph
Summary
The effects of targeted therapies for clear cell mRCC in patients naïve to systemic therapy, including combinations of tyrosine kinase inhibitors and immune checkpoint inhibitors, are assessed to assess the effects of these therapies on progression-free survival and overall survival.
- Type
- article
- Published
- 2020-10-14
- Cited by
- 3
- References
- 173
- Access
- Open access
- OpenAlex
- https://openalex.org/W2755395810
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:261236586
Keywords
Renal cell carcinoma, Medicine, Targeted therapy, Oncology, Systemic therapy
References
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
- Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.
- Stage migration and increasing proportion of favorable‐prognosis metastatic renal cell carcinoma patients
- Targeted therapy for advanced renal cell carcinoma.
- SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
- Immunotherapy for metastatic renal cell carcinoma.
- Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.
- Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.
- RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.
- Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma
- 4509 POSTER Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors
- Interpretation of random effects meta-analyses
- 4008 POSTER Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN)
- Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.
- A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma.
- Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
- 7121 Bevacizumab (BEV) and interferon (IFN) therapy does not increase risk of cardiac events in metastatic renal cell carcinoma (mRCC)
- Intracellular signal transduction pathway proteins as targets for cancer therapy.
- Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
Cited by
- Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review
- Assay of Bio Analytical Method for the Estimation of Avelumab and Axitinib Using UPLC and Its Application to Pharmacokinetic Studies
- Immune Checkpoint Inhibitors in Cancer Treatment and Incidence of Pancreatitis
Related papers
- 239P Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
- Progress of targeted therapy for renal cell carcinoma
- S&T-22 PROGNOSTIC SIGNIFICANCE OF NEPHRECTOMY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH FIRST-LINE SYSTEMIC THERAPY: A 10-YEAR RETROSPECTIVE ANALYSIS ACCORDING TO MSKCC AND HENG RISK CRITERIA
- Combination of targeted agents in metastatic renal cell carcinoma
- How can targeted therapy influence renal surgery for renal cell carcinoma?
- Status and progress of targeted therapy of renal cell carcinoma
- Targeted therapy in renal cell carcinoma